Table 3.

Effects of administration of everolimus and Cdc2 inhibitor on renal function in Nx rats

	Everolimus		2-Cyanoethyl Alsterpaullone
	E− (n = 8)	E+ (n = 6)	A− (n = 11)	A+ (n = 9)
Body weight, g	226.1 ± 5.3	171.9 ± 4.5‡	242.5 ± 3.6	222.7 ± 8.8*
Kidney weight/body weight, %	0.26 ± 0.01	0.22 ± 0.01†	0.24 ± 0.01	0.24 ± 0.01
Urine volume, ml/day	15.4 ± 1.8	17.7 ± 3.9	25.3 ± 2.0	29.1 ± 2.3
BUN, mg/dl	41.9 ± 4.8	68.1 ± 5.0†	39.2 ± 2.0	54.2 ± 7.2*
PCr, mg/dl	0.90 ± 0.07	1.17 ± 0.08†	1.07 ± 0.05	1.22 ± 0.01
CCr, ml·min−1·kg−1	2.83 ± 0.17	1.41 ± 0.16‡	2.69 ± 0.19	2.44 ± 0.27
Albumin excretion, mg/day	8.4 ± 4.5	2.4 ± 1.0	5.7 ± 1.5	11.8 ± 3.9

Data represent means ± SE for n rats. E− and A−, Nx rats administered vehicle; E+ and A+, Nx rats daily administered everolimus (2 mg/kg) and 2-cyanoethyl alsterpaullone (0.5 mg/kg) for 14 days, respectively.

^*P < 0.05,

^†P < 0.01,

^‡P < 0.001, significantly different from vehicle-treated rats.